1. McClung JP, Roneker CA, Mu W, Lisk DJ, Langlais P, et al. (2004)
Development of insulin resistance and obesity in mice overexpressing cellular
glutathione peroxidase. Proc Natl Acad Sci U S A 101: 8852–7.
2. Wang XD, Vatamaniuk MZ, Wang SK, Roneker CA, Simmons RA, et al.
(2008) Molecular mechanisms for hyperinsulinaemia induced by overproduction
of selenium-dependent glutathione peroxidase-1 in mice. Diabetologia 51: 1515–
24.
3. Speckmann B, Sies H, Steinbrenner H (2009) Attenuation of hepatic expression
and secretion of selenoprotein P by metformin. Biochem Biophys Res Commun
387: 158–63.
4. Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, et al.
(2010) A liver-derived secretory protein, selenoprotein P, causes insulin
resistance. Cell Metab 12: 483–95.
5. Misu H, Ishikura K, Kurita S, Takeshita Y, Ota T, et al. (2012) Inverse
Correlation between Serum Levels of Selenoprotein P and Adiponectin in
Patients with Type 2 Diabetes. PLoS One 7(4):e34952.
6. Yang SJ, Hwang SY, Choi HY, Yoo HJ, Seo JA, et al. (2011) Serum
selenoprotein P levels in patients with type 2 diabetes and prediabetes:
implications for insulin resistance, inflammation, and atherosclerosis. J Clin
Endocrin Metab 96: E1325–9.
7. Steinbrenner H, Speckmann B, Pinto A, Sies H (2011) High selenium intake and
increased diabetes risk: experimental evidence for interplay between selenium
and carbohydrate metabolism. J Clin Biochem Nutr 48: 40–5.
8. Bleys J, Navas-Acien A, Guallar E (2007) Serum selenium and diabetes in U.S.
adults. Diabetes Care 30: 829–834.
9. Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E (2009) Serum
selenium concentrations and diabetes in U.S. adults: National Health and
Nutrition Examination Survey (NHANES) 2003–2004. Environ Health Perspect
117: 1409–1413.
10. Stranges S, Galletti F, Farinaro E, D’Elia L, Russo O, et al. (2011) Associations
of selenium status with cardiometabolic risk factors: an 8-year follow-up analysis
of the Olivetti Heart study. Atherosclerosis 217: 274–8.
11. Czernichow S, Couthouis A, Bertrais S, Vergnaud AC, Dauchet L, et al. (2006)
Antioxidant supplementation does not affect fasting plasma glucose in the
Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) study
in France: association with dietary intake and plasma concentrations. Am J Clin
Nutr 84: 395–399.
12. Akbaraly TN, Arnaud J, Rayman MP, Hininger-Favier I, Roussel AM, et al.
(2010) Plasma selenium and risk of dysglycemia in an elderly French population:
results from the prospective Epidemiology of Vascular Ageing Study. Nutr
Metab (Lond) 7: 21–7.
13. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, et al. (2007)
Effects of long-term selenium supplementation on the incidence of type 2
diabetes: a randomized trial. Ann Intern Med 147: 217–223.
14. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, et al. (2009)
Effect of selenium and vitamin E on risk of prostate cancer and other cancers:
the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301:
39–51.
15. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, et al. (2011)
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer
Prevention Trial (SELECT). JAMA 306: 1549–56.
16. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, et al. (2000) Plasma
concentrations of a novel, adipose-specific protein, adiponectin, in type 2
diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595–9.
17. Li S, Shin HJ, Ding EL, van Dam RM (2009) Adiponectin levels and risk of type
2 diabetes: a systematic review and meta-analysis. JAMA 302: 179–88.
18. Thorand B, Zierer A, Baumert J, Meisinger C, Herder C, et al. (2010)
Associations between leptin and the leptin/adiponectin ratio and incident Type
2 diabetes in middle-aged men and women: results from the MONICA/KORA
Augsburg study 1984–2002. Diabet Med 27: 1004–11.
19. Zhu N, Pankow JS, Ballantyne CM, Couper D, Hoogeveen RC, et al. (2010)
High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC
study. J Clin Endocrinol Metab 95: 5097–104.
20. Montonen J, Drogan D, Joost HG, Boeing H, Fritsche A, et al. (2011) Estimation
of the contribution of biomarkers of different metabolic pathways to risk of type
2 diabetes. Eur J Epidemiol 26: 29–38.
21. Qatanani M, Lazar MA (2007) Mechanisms of obesity-associated insulin
resistance: many choices on the menu. Genes Dev 21: 1443–55.
22. Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors.
Endocr Rev 26: 439–51.
23. Schoenmakers E, Agostini M, Mitchell C, Schoenmakers N, Papp L, et al. (2010)
Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead
to a multisystem selenoprotein deficiency disorder in humans. J Clin Invest 120:
4220–35.
24. Vunta H, Davis F, Palempalli UD, Bhat D, Arner RJ, et al. (2007) The antiinflammatory
effects of selenium are mediated through 15-deoxy-Delta12,14-
prostaglandin J2 in macrophages. J Biol Chem 282: 17964–73.
25. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, et al. (2001)
PPARgamma ligands increase expression and plasma concentrations of
adiponectin, an adipose-derived protein. Diabetes 50: 2094–9.
26. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, et al. (2002) Induction
of adipocyte complement-related protein of 30 kilodaltons by PPARgamma
agonists: a potential mechanism of insulin sensitization. Endocrinology 143:
998–1007.
27. Zhang Y, Chen X (2011) Reducing selenoprotein P expression suppresses
adipocyte differentiation as a result of increased preadipocyte inflammation.
Am J Physiol Endocrinol Metab 300: E77–85.
28. Salas-Salvado´ J, Granada M, Bullo´ M, Corominas A, Casas P, et al. (2007)
Plasma adiponectin distribution in a Mediterranean population and its
association with cardiovascular risk factors and metabolic syndrome. Metabolism
56: 1486–92.
29. Rayman MP, Stranges S, Griffin BA, Pastor-Barriuso R, Guallar E (2011) Effect
of supplementation with high-selenium yeast on plasma lipids: a randomised
trial. Ann Intern Med 54: 656–665.
30. Rayman MP (2011) Selenium and adverse conditions of human pregnancy. In:
Hatfield DL, Berry MJ and Gladyshev VN, editors. Selenium: Its molecular
biology and role in human health. 3rd ed. New York, NY: Springer
Science+Business Media, LLC. Chapter 42, 531–546.
31. Gavrila A, Peng CK, Chan JL, Mietus JE, Goldberger AL, et al. (2003) Diurnal
and ultradian dynamics of serum adiponectin in healthy men: comparison with
leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol
Metab 88: 2838–43.
32. Shand B, Elder P, Scott R, Frampton C, Willis J (2006)) Biovariability of plasma
adiponectin. Clin Chem Lab Med 44: 1264–8.
33. Rayman MP, Thompson A, Warren-Perry M, Galassini R, Catterick J, et al.
(2006) Impact of selenium on mood and quality of life: a randomised controlled
trial. Biol Psychiatry 59: 147–54.
34. Rayman MP, Thompson AJ, Bekaert B, Catterick J, Galassini R, et al. (2008)
Randomized controlled trial of the effect of selenium supplementation on
thyroid function in the elderly in the United Kingdom. Am J Clin Nutr 87: 370–
8.
35. CRC Handbook of Chemistry and Physics (1993–1994) 74th edition, David R.
Lide, editor. Boca Raton, USA: CRC Press.
36. Houstis N, Rosen ED, Lander ES (2006) Reactive oxygen species have a causal
role in multiple forms of insulin resistance. Nature 440: 944–48.
37. Labunskyy VM, Lee BC, Handy DE, Loscalzo J, Hatfield DL, et al. (2011) Both
maximal expression of selenoproteins and selenoprotein deficiency can promote
development of type 2 diabetes-like phenotype in mice. Antioxid Redox Signal
14: 2327–36.
38. Pinto A, Juniper DT, Sanil M, Morgan L, Clark L, et al. (2012) Supranutritional
selenium induces alterations in molecular targets related to energy metabolism in
skeletal muscle and visceral adipose tissue of pigs. J Inorg Biochem 114C: 47–54.
39. Kantartzis K, Fritsche A, Tschritter O, Thamer C, Haap M, et al. (2005) The
association between plasma adiponectin and insulin sensitivity in humans
depends on obesity. Obes Res 13: 1683–91.
40. Stenholm S, Koster A, Alley DE, Visser M, Maggio M, et al. (2010)
Adipocytokines and the metabolic syndrome among older persons with and
without obesity: the InCHIANTI study. Clin Endocrinol (Oxf) 73: 55–65.
41. You T, Nicklas BJ, Ding J, Penninx BW, Goodpaster BH, et al. (2008) The
metabolic syndrome is associated with circulating adipokines in older adults
across a wide range of adiposity. J Gerontol A Biol Sci Med Sci 63: 414–9.
42. Mueller AS, Bosse AC, Most E, Klomann SD, Schneider S, et al. (2009))
Regulation of the insulin antagonistic protein tyrosine phosphatase 1B by dietary
Se studied in growing rats. J Nutr Biochem 20: 235–247.
43. Mueller AS, Mueller K, Wolf NM, Pallauf J (2009) Selenium and diabetes: an
enigma? Free Radic Res 43: 1029–1059.
44. Hurst R, Armah CN, Dainty JR, Hart DJ, Teucher B, et al. (2010) Establishing
optimal selenium status: results of a randomized, double-blind, placebocontrolled
trial. Am J Clin Nutr 91: 923–31.
45. Stranges S, Navas-Acien A, Rayman MP, Guallar E (2010) Selenium status and
cardio-metabolic health: state of the evidence. Nut Metab Cardiovasc Dis 20:
754–60.
46. Hu Y, McIntosh GH, Le Leu RK, Upton JM, Woodman RJ, et al. (2011) The
influence of selenium-enriched milk proteins and selenium yeast on plasma
selenium levels and rectal selenoprotein gene expression in human subjects.
Br J Nutr 106: 572–82.
47. Alizadeh M, Safaeiyan A, Ostadrahimi A, Estakhri R, Daneghian S, et al. (2012)
Effect of L-arginine and selenium added to a hypocaloric diet enriched with
legumes on cardiovascular disease risk factors in women with central obesity: a
randomized, double-blind, placebo-controlled trial. Ann Nutr Metab 60: 157–
68.
48. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, et al. (2002) The effect of
thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2
diabetic subjects. Diabetes 51: 2968–74.